Administration of butaperazine and plasma methionine-enkephalin levels in schizophrenic and affective disorder patients with tardive dyskinesia.
The levels of plasma methionine-enkephalin in male chronic schizophrenic and affective disorder patients with or without tardive dyskinesia (TD) were in a range similar to those of sex-matched adult control volunteers. Administration of butaperazine resulted in significant changes (increases) of neuropeptide plasma concentration only in the affective disorder with TD subgroup, reaching statistical significance over their own baseline at 8, 10.5, and 24 hours, and at baseline (0 hr), 8-, and 48-hour intervals when compared with the affective disorder patients without TD.
Mosnaim
A D
AD
Department of Pharmacology, University of Health Sciences, Chicago Medical School, North Chicago, IL 60064.
Wolf
M E
ME
D000293:Adolescent; D000328:Adult; D004409:Dyskinesia, Drug-Induced / Q000097:blood* / Q000150:complications; D004744:Enkephalin, Methionine / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D019964:Mood Disorders / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D010640:Phenothiazines / Q000009:adverse effects* / Q000627:therapeutic use; D011863:Radioimmunoassay; D012559:Schizophrenia / Q000097:blood / Q000150:complications* / Q000188:drug therapy
D010640:Phenothiazines; D004744:Enkephalin, Methionine